µÏÍþ¹ú¼Ê

µÏÍþÖÆµÏÍþ¹ú¼Ê µÏÍþÖÆµÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
2024 WCLCÔ¤¸æ | µÏÍþÖÆµÏÍþ¹ú¼Ê¶àÏî´´ÐÂÑо¿ÁÁÏà¹ú¼ÊѧÊõÊ¢»á
·¢²¼ÈÕÆÚ£º2024/08/23
×ÖºÅ

2024ÄêÊÀ½ç·Î°©´ó»á£¨WCLC£©½«ÓÚµ±µØÊ±¼ä9ÔÂ7ÈÕÖÁ10ÈÕÔÚÃÀ¹úÊ¥µØÑǸçÕÙ¿ª¡£ÔÚ´ó»á¹«²¼µÄ¡°×îÐÂÍ»ÆÆÕªÒª(Late Breaking Abstract£¬LBA)¡±Ãûµ¥ÖУ¬µÏÍþÖÆµÏÍþ¹ú¼ÊÔ­Ñд´ÐµÏÍþ¹ú¼Ê°¢ÃÀÌæÄá¼°±¸ÊܹØ×¢µÄ¹ÜÏß²úÆ·HS-20093ƾ½èÓÅÒìµÄÑо¿½á¹û˫˫ÈëÑ¡£»°¢ÃÀÌæÄáÁíÓÐ12ƪ´´Ð³ɹûÈëÑ¡±¾½ì´ó»á£¬ÄÚÈݺ­¸Çи¨Öú¡¢¸¨Öú¡¢ÁªºÏ»¯ÁÆ¡¢ÁªºÏ·ÅÁÆ¡¢ÄÔ×ªÒÆµÈÁìÓò¡£



Part 1£º×îÐÂÍ»ÆÆÕªÒª£¨LBA£©




¡¾1.1¡¿ Aumolertinib Maintenance after Chemoradiotherapy in stage ¢ó Non-Small-Cell Lung Cancer: Interim Results of the phase ¢ó study (POLESTAR)

°¢ÃÀÌæÄáÓÃÓÚ·Å»¯Áƺó¢óÆÚ·ÇСϸ°û·Î°©µÄά³ÖÖÎÁÆ£º¢óÆÚÑо¿£¨POLESTAR£©µÄÖÐÆÚ½á¹û

×÷ÕߣºÓÚ½ðÃ÷¡¢ÃÏÏ鿝£¨É½¶«µÚÒ»Ò½¿Æ´óѧ¸½ÊôÖ×ÁöÒ½Ôº£©

¡¾1.2¡¿ Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase ¢ñ Study (ARTEMIS-001)

Ò»Ïî¶àÖÐÐÄ¡¢¢ñÆÚÑо¿£¨ARTEMIS-O01£©ÖÐ HS-20093 ÖÎÁƹ㷺ÆÚСϸ°û·Î°©µÄÁÆÐ§ºÍ°²È«ÐÔ

×÷ÕߣºÍõ½à£¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£© 


Part 2£ºÃÔÄã¿ÚÍ·±¨¸æ




¡¾2.1¡¿ Aumolertinib as adjuvant therapy in resectable ¢ñ-¢ó EGFR-mutant NSCLC : also effective in patients with high-risk relapse factors

°¢ÃÀÌæÄá×÷Ϊ¿ÉÇгý¢ñ-¢óÆÚEGFRÍ»±äNSCLC µÄ¸¨ÖúÖÎÁÆ£º¶Ô¾ßÓи´·¢¸ßΣÒòËØ»¼ÕßÒ²ÓÐЧ

×÷ÕߣºÒ¦½¡£¨¼ªÁÖÊ¡ÈËÃñÒ½Ôº£©


Part 3£ºÑо¿Éè¼Æ




¡¾3.1¡¿ MRD guiding treatment after Aumolertinib induction therapy for EGFRm+ stage ¢ó NSCLC in the MDT diagnostic model (APPROACH)

MDTÕïÁÆÄ£Ê½ÏÂEGFRÍ»±äÑôÐÔ²»¿ÉÇгý¢óÆÚ·ÇСϸ°û·Î°©¾­°¢ÃÀÌæÄáÓÕµ¼ÖÎÁƺóMRD¶¯Ì¬¼à²âÖ¸µ¼ÖÎÁƾö²ßµÄÓÐЧÐԺͰ²È«ÐÔÑо¿£ºÒ»Ï·ÅÐÔ¡¢¶àÖÐÐÄ¡¢¢óÆÚÁÙ´²Ñо¿

×÷ÕߣºÖÜÇå¡¢ÎâÒ»Áú£¨¹ã¶«Ê¡ÈËÃñÒ½Ôº£©

¡¾Öйúר³¡ÌÖÂÛ±Ú±¨¡¿


¡¾3.2¡¿ Efficacy and safety of Aumolertinib with radiotherapy in the treatment of unresectable locally advanced EGFR-mutant NSCLC: a phase ¢ò study

°¢ÃÀÌæÄáÁªºÏ·ÅÁÆÖÎÁƲ»¿ÉÇоÖÍíÆÚµÄEGFRÍ»±äNSCLCµÄÁÆÐ§ºÍ°²È«ÐÔ:Ò»Ïî¢òÆÚÑо¿

×÷ÕߣºÃÏÏ齿£¨É½¶«Ê¡Ö×ÁöÒ½Ôº£©



Part 4£ºÑо¿Êý¾Ý




¡¾4.1¡¿ Aumolertinib as neoadjuvant therapy for EGFRm+ NSCLC: a subcohort analysis of PURPOSE trial data updated

°¢ÃÀÌæÄáи¨ÖúÖÎÁÆEGFRÍ»±äNSCLC»¼ÕߣºPURPOSEÊÔÑéµÄ¶ÓÁзÖÎö

×÷Õߣº·½ÎÄÌΣ¨ÉϺ£ÊÐÐØ¿ÆÒ½Ôº£©


¡¾4.2¡¿ Aumolertinib in treatment-na?ve EGFR-mutant NSCLC patients with brain metastases: efficacy and safety data from the ARTISTRY

°¢ÃÀÌæÄáÖÎÁƳõÕï·ÇСϸ°û·Î°©£¨NSCLC£©°éÄÔ×ªÒÆµÄÓÐЧÐÔÓ밲ȫÐÔ£ºARTISTRYÑо¿¶ÓÁÐ1

×÷ÕߣºÕÅÏþ¾ê¡¢Íõ»Û¾ê£¨ºÓÄÏÊ¡Ö×ÁöÒ½Ôº£©


¡¾4.3¡¿ Aumolertinib with chemotherapy as first-line treatment in patients with EGFR-mutated advanced NSCLC: a real-world study

°¢ÃÀÌæÄáÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚNSCLC»¼ÕߣºÒ»ÏîÕæÊµÊÀ½çÑо¿

×÷ÕߣºÐí¼ÑÀö¡¢¹ùÈË»¨£¨½­ËÕÊ¡ÈËÃñÒ½Ôº£©


¡¾4.4¡¿ Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage ¢ñ NSCLC with multiple high-risk factors

°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÍ»±ä°é¶àÖØ¸ßΣÒòËØµÄ¢ñÆÚNSCLC

×÷ÕߣºÎâÆë·É£¨Î÷°²½»´óÒ»¸½Ôº£©


¡¾4.5¡¿ Safety and efficacy of cranial radiotherapy in combination with Aumolertinib in EGFR-mutant NSCLC patients with brain metastases

EGFRÍ»±ä·ÇСϸ°û·Î°©ÄÔ×ªÒÆ°¢ÃÀÌæÄáÁªºÏ¾«×¼·ÅÁƵÄÁÆÐ§ºÍ°²È«ÐÔ

×÷Õߣº±Ï骣¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£©


¡¾4.6¡¿ Adjuvant Aumolertinib in resected stage I EGFR-mutated NSCLC: prospectively evaluating efficacy in residual GGN lesions

°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±äIÆÚ·Î°©ÇгýÊõºó²ÐÁô·ÎÄ¥²£Á§½á½Ú

×÷Õߣº»Æ³ç±ê£¨Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº£©


¡¾4.7¡¿ Adjuvant Aumolertinib in patients with completely resected, stage ¢ñA2-¢óA Non-Small-Cell Lung Cancer with uncommon EGFR mutations

°¢ÃÀÌæÄḨÖúÖÎÁÆ¢ñA2-¢óAÆÚº±¼ûEGFRÍ»±äNSCLC»¼Õß

×÷Õߣººú¼á£¨Õã½­´óѧҽѧԺ¸½ÊôµÚÒ»Ò½Ôº£©


¡¾4.8¡¿ Efficacy and safety of Aumolertinib in stage ¢ñB-¢óA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status

°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁÆR0ÇгýµÄ¢ñB-¢óAÆÚNSCLC»¼ÕßµÄÁÆÐ§ºÍ°²È«ÐÔÒÔ¼°ÊõºóMRDÓëÁÆÐ§Ïà¹ØÐÔµÄÑо¿

×÷ÕߣºÑîʤÀû£¨·ðɽÊеÚÒ»ÈËÃñÒ½Ôº£©


Part 5£º²¡ÀýϵÁÐ




¡¾5.1¡¿ High-dose Aumolertinib combined intrathecal chemotherapy for the treatment of EGFR-mutated NSCLC with leptomeningeal metastasis

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÁªºÏÇÊÄÚ»¯ÁÆÖÎÁÆEGFRÍ»±äNSCLC°éÄÔÄ¤×ªÒÆ

×÷ÕߣºÍõΰ£¨ÖØÇì´óѧ¸½ÊôÈýϿҽԺ£©


¹ØÓÚµÏÍþÖÆµÏÍþ¹ú¼Ê

µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬´´ÐµÏÍþ¹ú¼ÊÓªÊÕÕ¼±ÈÒÑÍ»ÆÆÖÁ67.9%¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£


  Ç°Õ°ÐÔ˵Ã÷

±¾ÎÄÖ¼ÔÚÌṩÓйء°µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬²»¹¹³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£

±¾ÎÄËù·¢²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üº¬Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬ÀýÈçÉæ¼°ÒµÎñºÍ²úƷǰ¾°£¬»ò¹«Ë¾¼Æ»®¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°²ßÂÔ¡£ÕâЩ±íÊöÊǽ¨Á¢ÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÔ¤²â£¬²¢·ÇÊǶÔδÀ´·¢Õ¹µÄ±£Ö¤£¬ÒòÆäÐÔÖÊʹȻ¾ùÊÜÏà¹Ø·çÏպͲ»È·¶¨ÒòËØÓ°Ï죬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬Í¶×ÊÕß½øÐÐͶ×ʾö²ßʱӦ½÷É÷ʹÓá£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï½øÐбíÊöʱ£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬¹«Ë¾¡¢¹«Ë¾¶­Ê¡¢¹ÍÔ±¡¢´úÀí¸Å²»³Ðµ£ÒòÈκÎǰհÐÔ±íÊö²»ÄÜʵÏÖ»ò±ä³É²»ÕýÈ·¶øÒýÖµÄÈκÎÔðÈΡ£

±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬ÎÞÂÛÊÇ·ñ³öÏÖÐÂ×ÊÁÏ¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö£¬³ý·Ç·¨ÂÉÒªÇ󣬹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£Í¶×ÊÕßÒ˲ÎÕÕµÏÍþÖÆµÏÍþ¹ú¼Ê£¨03692.HK£©¹«¸æ¼°²Æ±¨£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£


¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿